Immuneering Analyst Price Targets - Benzinga

Immuneering Corp

IMRXNASDAQ

Trade with Public

Trade with Public

$5.04

0.020.4%

At close: Sep 3, 5:00 PM EST

$5.00

-0.04-0.79%

After Hours: 4:11 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Immuneering Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immuneering (IMRX).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

7Buy

3Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$15Upside to Avg. PT+202.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 6, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Initiate	Buy	$14
Jul 20, 2026	Needham	Ami Fadia	PT Raise	Buy	$11→$18
Jul 8, 2026	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
May 19, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$20
Mar 9, 2026	Needham	Ami Fadia	Maintained	Buy	$11
Nov 13, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$20
Oct 31, 2025	Leerink Partners	Andrew Berens	Initiate	Outperform	$15
Sep 30, 2025	HC Wainwright & Co.	Ami Fadia	Maintained	Buy	$11
Sep 26, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$13→$20
Sep 25, 2025	Oppenheimer	Jay Olson	PT Raise	Outperform	$21→$30
Sep 15, 2025	Needham	Ami Fadia	PT Raise	Buy	$8→$11
Aug 26, 2025	Needham	Ami Fadia	Maintained	Buy	$8
Aug 14, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$13
Jun 18, 2025	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$8→$10
Jun 18, 2025	Needham	Ami Fadia	Maintained	Buy	$9
Jun 18, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$13
Jun 5, 2025	Needham	Ami Fadia	Maintained	Buy	$9
May 7, 2025	Oppenheimer	Jay Olson	PT Cut	Outperform	$25→$21
May 6, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$13
Apr 10, 2025	Needham	Ami Fadia	Maintained	Buy	$12

More with Benzinga EdgeGet Access

Analyst Ratings News

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14

HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $14.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Immuneering, Raises Price Target to $18

Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Immuneering with Overweight Rating

Cantor Fitzgerald analyst Li Watsek initiates coverage on Immuneering (NASDAQ:IMRX) with a Overweight rating.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Immuneering, Maintains $11 Price Target

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $11 price target.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Immuneering, Maintains $20 Price Target

Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $20 price target.

Benzinga Newsdesk